Mechanisms for Activation of Beige Adipose Tissue in Humans

Study overview

Mirabegron (Myrbetriq®, Astellas) is a highly specific and well-tolerated ß3 agonist marketed for overactive bladder. This trial will assess the effects of mirabegron on glucose tolerance and adipose tissue in prediabetic patients

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Collaborators and Investigators

Philip Kern,

Philip Kern, MD, PRINCIPAL_INVESTIGATOR, University of Kentucky

Study Record Dates

2024-12-31